Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 282

1.

Subthalamic deep brain stimulation and impulse control in Parkinson's disease.

Hälbig TD, Tse W, Frisina PG, Baker BR, Hollander E, Shapiro H, Tagliati M, Koller WC, Olanow CW.

Eur J Neurol. 2009 Apr;16(4):493-7. doi: 10.1111/j.1468-1331.2008.02509.x.

PMID:
19236471
2.

The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism.

Tse W, Frisina PG, Hälbig TD, Gracies JM, Liang L, Tarshish C, Lesser G, Neufeld R, Koller WC, Libow LS.

J Am Med Dir Assoc. 2008 Nov;9(9):670-5. doi: 10.1016/j.jamda.2008.07.001. Epub 2008 Sep 25.

PMID:
18992700
3.

Levodopa.

Hälbig TD, Koller WC.

Handb Clin Neurol. 2007;84:31-72. doi: 10.1016/S0072-9752(07)84032-2. No abstract available.

PMID:
18808941
4.

Preface.

Koller WC, Melamed E.

Handb Clin Neurol. 2007;84:IX. doi: 10.1016/S0072-9752(07)84064-4. No abstract available.

PMID:
18808937
5.

Preface.

Koller WC, Melamed E.

Handb Clin Neurol. 2007;83:IX. doi: 10.1016/S0072-9752(07)83032-6. No abstract available.

PMID:
18808906
6.

A comparison of Parkinson's disease symptoms and self-reported functioning and well being.

Lyons KE, Pahwa R, Troster AI, Koller WC.

Parkinsonism Relat Disord. 1997 Dec;3(4):207-9.

PMID:
18591077
7.

Prevalence of movement disorders in an elderly nursing home population.

Tse W, Libow LS, Neufeld R, Lesser G, Frank J, Dolan S, Tarshish C, Gracies JM, Olanow CW, Koller WC, Hälbig TD.

Arch Gerontol Geriatr. 2008 May-Jun;46(3):359-66. Epub 2007 Jun 26.

PMID:
17597235
8.

Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.

Pahwa R, Koller WC, Trosch RM, Sherry JH; APO303 Study Investigators.

J Neurol Sci. 2007 Jul 15;258(1-2):137-43. Epub 2007 Apr 27.

PMID:
17466338
9.

Absence of the apolipoprotein E epsilon4 allele is associated with working memory impairment in Parkinson's disease.

Tröster AI, Fields JA, Paolo AM, Koller WC.

J Neurol Sci. 2006 Oct 25;248(1-2):62-7.

PMID:
16769085
10.

Topiramate in essential tremor: a double-blind, placebo-controlled trial.

Ondo WG, Jankovic J, Connor GS, Pahwa R, Elble R, Stacy MA, Koller WC, Schwarzman L, Wu SC, Hulihan JF; Topiramate Essential Tremor Study Investigators.

Neurology. 2006 Mar 14;66(5):672-7. Epub 2006 Jan 25.

PMID:
16436648
11.

The diagnosis of manganese-induced parkinsonism.

Cersosimo MG, Koller WC.

Neurotoxicology. 2006 May;27(3):340-6. Epub 2005 Dec 1. Review.

PMID:
16325915
12.

Clinical usefulness of the Parkinson's disease sleep scale.

Tse W, Liu Y, Barthlen GM, Hälbig TD, Tolgyesi SV, Gracies JM, Olanow CW, Koller WC.

Parkinsonism Relat Disord. 2005 Aug;11(5):317-21.

PMID:
15882956
13.

A novel formulation of selegiline for the treatment of Parkinson's disease.

Tetrud JW, Koller WC.

Neurology. 2004 Oct 12;63(7 Suppl 2):S2-6. Review. No abstract available.

PMID:
15477582
14.

Unilateral stimulation of the subthalamic nucleus in Parkinson disease: a double-blind 12-month evaluation study.

Germano IM, Gracies JM, Weisz DJ, Tse W, Koller WC, Olanow CW.

J Neurosurg. 2004 Jul;101(1):36-42.

PMID:
15255249
15.

Neuroprotection in Parkinson's disease: an elusive goal.

Koller WC, Cersosimo MG.

Curr Neurol Neurosci Rep. 2004 Jul;4(4):277-83. Review.

PMID:
15217541
16.

Apolipoprotein E controls the risk and age at onset of Parkinson disease.

Li YJ, Hauser MA, Scott WK, Martin ER, Booze MW, Qin XJ, Walter JW, Nance MA, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Jankovic J, Goetz CG, Small GW, Mastaglia F, Haines JL, Pericak-Vance MA, Vance JM.

Neurology. 2004 Jun 8;62(11):2005-9.

PMID:
15184605
17.

Advances in the treatment of Parkinson's disease.

Pahwa R, Koller WC.

Drugs Today (Barc). 1998 Feb;34(2):95-105.

PMID:
15094867
18.

Effect of levodopa treatment for parkinsonism in welders: A double-blind study.

Koller WC, Lyons KE, Truly W.

Neurology. 2004 Mar 9;62(5):730-3.

PMID:
15007122
19.

Effect of motor improvement on quality of life following subthalamic stimulation is mediated by changes in depressive symptomatology.

Tröster AI, Fields JA, Wilkinson S, Pahwa R, Koller WC, Lyons KE.

Stereotact Funct Neurosurg. 2003;80(1-4):43-7.

PMID:
14745208
20.

Unmet medical needs in Parkinson's disease.

Koller WC, Tse W.

Neurology. 2004 Jan 13;62(1 Suppl 1):S1-8. Review.

PMID:
14718675
21.

Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease.

Li YJ, Oliveira SA, Xu P, Martin ER, Stenger JE, Scherzer CR, Hauser MA, Scott WK, Small GW, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Jankovic J, Goetz CG, Mastaglia F, Middleton LT, Roses AD, Saunders AM, Schmechel DE, Gullans SR, Haines JL, Gilbert JR, Vance JM, Pericak-Vance MA, Hulette C, Welsh-Bohmer KA.

Hum Mol Genet. 2003 Dec 15;12(24):3259-67. Epub 2003 Oct 21. Erratum in: Hum Mol Genet. 2004 Mar 1;13(5):573.

PMID:
14570706
22.

Association study of Parkin gene polymorphisms with idiopathic Parkinson disease.

Oliveira SA, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons KE, Pahwa R, Stern MB, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Scott BL, Goetz CG, Small GW, Mastaglia FL, Stajich JM, Zhang F, Booze MW, Reaves JA, Middleton LT, Haines JL, Pericak-Vance MA, Vance JM, Martin ER.

Arch Neurol. 2003 Jul;60(7):975-80.

PMID:
12873854
23.

Movement disorders.

Cersosimo MG, Koller WC.

Med Clin North Am. 2003 Jul;87(4):771-91, vii.

PMID:
12834148
24.

Benefits and risks of pharmacological treatments for essential tremor.

Lyons KE, Pahwa R, Comella CL, Eisa MS, Elble RJ, Fahn S, Jankovic J, Juncos JL, Koller WC, Ondo WG, Sethi KD, Stern MB, Tanner CM, Tintner R, Watts RL.

Drug Saf. 2003;26(7):461-81. Review.

PMID:
12735785
25.

Parkin mutations and susceptibility alleles in late-onset Parkinson's disease.

Oliveira SA, Scott WK, Martin ER, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Ondo WG, Allen FH Jr, Scott BL, Goetz CG, Small GW, Mastaglia F, Stajich JM, Zhang F, Booze MW, Winn MP, Middleton LT, Haines JL, Pericak-Vance MA, Vance JM.

Ann Neurol. 2003 May;53(5):624-9.

PMID:
12730996
26.

Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease.

van der Walt JM, Martin ER, Scott WK, Zhang F, Nance MA, Watts RL, Hubble JP, Haines JL, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Goetz CG, Small GW, Mastaglia F, Roses AD, Stajich JM, Booze MW, Fujiwara K, Gibson RA, Middleton LT, Scott BL, Pericak-Vance MA, Vance JM.

Neurology. 2003 Apr 8;60(7):1189-91.

PMID:
12682333
27.

Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease.

van der Walt JM, Nicodemus KK, Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Haines JL, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Goetz CG, Small GW, Mastaglia F, Stajich JM, McLaurin AC, Middleton LT, Scott BL, Schmechel DE, Pericak-Vance MA, Vance JM.

Am J Hum Genet. 2003 Apr;72(4):804-11. Epub 2003 Feb 28.

28.

Neuropsychological and quality of life outcomes 12 months after unilateral thalamic stimulation for essential tremor.

Fields JA, Tröster AI, Woods SP, Higginson CI, Wilkinson SB, Lyons KE, Koller WC, Pahwa R.

J Neurol Neurosurg Psychiatry. 2003 Mar;74(3):305-11.

29.

Differential diagnosis of parkinsonism.

Facca AG, Koller WC.

Adv Neurol. 2003;91:383-96. Review. No abstract available.

PMID:
12442697
30.

An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype.

Poorkaj P, Muma NA, Zhukareva V, Cochran EJ, Shannon KM, Hurtig H, Koller WC, Bird TD, Trojanowski JQ, Lee VM, Schellenberg GD.

Ann Neurol. 2002 Oct;52(4):511-6.

PMID:
12325083
31.

Magnitude of microelectrode refinement in pallidotomy and thalamotomy.

Milligan BD, Wilkinson S, Overman J, Kirschman DL, Koller WC, Pahwa R, Lyons KE, Batnitzky S, Gordon MA.

Stereotact Funct Neurosurg. 2001;76(1):2-18.

PMID:
12007274
32.

Thalamic stimulation for midbrain tremor after partial hemangioma resection.

Pahwa R, Lyons KE, Kempf L, Wilkinson SB, Koller WC.

Mov Disord. 2002 Mar;17(2):404-7.

PMID:
11921133
33.

Treatment of early Parkinson's disease.

Koller WC.

Neurology. 2002 Feb 26;58(4 Suppl 1):S79-86. Review.

PMID:
11909989
34.

Neuropsychological deficits in essential tremor: an expression of cerebello-thalamo-cortical pathophysiology?

Tröster AI, Woods SP, Fields JA, Lyons KE, Pahwa R, Higginson CI, Koller WC.

Eur J Neurol. 2002 Mar;9(2):143-51.

PMID:
11882055
35.

Age at onset in two common neurodegenerative diseases is genetically controlled.

Li YJ, Scott WK, Hedges DJ, Zhang F, Gaskell PC, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, Jankovic J, Allen FA Jr, Goetz CG, Mastaglia F, Stajich JM, Gibson RA, Middleton LT, Saunders AM, Scott BL, Small GW, Nicodemus KK, Reed AD, Schmechel DE, Welsh-Bohmer KA, Conneally PM, Roses AD, Gilbert JR, Vance JM, Haines JL, Pericak-Vance MA.

Am J Hum Genet. 2002 Apr;70(4):985-93. Epub 2002 Mar 1.

36.

Thalamic stimulation reduces essential tremor but not the delayed antagonist muscle timing.

Zackowski KM, Bastian AJ, Hakimian S, Mink JW, Perlmutter JS, Koller WC, Thach WT Jr.

Neurology. 2002 Feb 12;58(3):402-10.

PMID:
11839839
37.

Neuropsychological and quality of life changes following unilateral thalamic deep brain stimulation in Parkinson's disease: a one-year follow-up.

Woods SP, Fields JA, Lyons KE, Koller WC, Wilkinson SB, Pahwa R, Tröster AI.

Acta Neurochir (Wien). 2001 Dec;143(12):1273-7; discussion 1278.

PMID:
11810392
38.

Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease.

Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Goetz CG, Small GW, Masterman D, Mastaglia F, Laing NG, Stajich JM, Ribble RC, Booze MW, Rogala A, Hauser MA, Zhang F, Gibson RA, Middleton LT, Roses AD, Haines JL, Scott BL, Pericak-Vance MA, Vance JM.

JAMA. 2001 Nov 14;286(18):2245-50.

39.

Complete genomic screen in Parkinson disease: evidence for multiple genes.

Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K, Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen FH Jr, Goetz CG, Small GW, Masterman D, Mastaglia F, Laing NG, Stajich JM, Slotterbeck B, Booze MW, Ribble RC, Rampersaud E, West SG, Gibson RA, Middleton LT, Roses AD, Haines JL, Scott BL, Vance JM, Pericak-Vance MA.

JAMA. 2001 Nov 14;286(18):2239-44.

PMID:
11710888
40.

Essential tremor in twins: an assessment of genetic vs environmental determinants of etiology.

Tanner CM, Goldman SM, Lyons KE, Aston DA, Tetrud JW, Welsh MD, Langston JW, Koller WC.

Neurology. 2001 Oct 23;57(8):1389-91.

PMID:
11673577
41.

Long term safety and efficacy of unilateral deep brain stimulation of the thalamus for parkinsonian tremor.

Lyons KE, Koller WC, Wilkinson SB, Pahwa R.

J Neurol Neurosurg Psychiatry. 2001 Nov;71(5):682-4.

42.

Parkinson's disease. Update in diagnosis and symptom management.

Marjama-Lyons JM, Koller WC.

Geriatrics. 2001 Aug;56(8):24-5, 29-30, 33-5. Review.

PMID:
11505857
43.

Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism.

Fukuda M, Mentis MJ, Ma Y, Dhawan V, Antonini A, Lang AE, Lozano AM, Hammerstad J, Lyons K, Koller WC, Moeller JR, Eidelberg D.

Brain. 2001 Aug;124(Pt 8):1601-9.

PMID:
11459751
44.

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines.

Olanow CW, Watts RL, Koller WC.

Neurology. 2001 Jun;56(11 Suppl 5):S1-S88. Review. No abstract available.

PMID:
11402154
45.

A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor.

Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, Dubinsky RM, Friedman JH, Manyam BV, Matsumoto JY, Pullman SL, Rajput AH, Sethi KD, Tanner C, Koller WC.

Neurology. 2001 Jun 12;56(11):1523-8.

PMID:
11402109
46.

Long-term safety and efficacy of unilateral deep brain stimulation of the thalamus in essential tremor.

Koller WC, Lyons KE, Wilkinson SB, Troster AI, Pahwa R.

Mov Disord. 2001 May;16(3):464-8.

PMID:
11391740
47.

Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study.

Hutton JT, Metman LV, Chase TN, Juncos JL, Koller WC, Pahwa R, LeWitt PA, Samii A, Tsui JK, Calne DB, Waters CH, Calabrese VP, Bennett JP, Barrett R, Morris JL.

Mov Disord. 2001 May;16(3):459-63.

PMID:
11391739
48.

The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.

Heikkinen H, Nutt JG, LeWitt PA, Koller WC, Gordin A.

Clin Neuropharmacol. 2001 May-Jun;24(3):150-7.

PMID:
11391126
49.

Comparison of thalamotomy to deep brain stimulation of the thalamus in essential tremor.

Pahwa R, Lyons KE, Wilkinson SB, Tröster AI, Overman J, Kieltyka J, Koller WC.

Mov Disord. 2001 Jan;16(1):140-3.

PMID:
11215575
50.

Deep brain stimulation of the Vim nucleus of the thalamus for the treatment of tremor.

Koller WC, Pahwa PR, Lyons KE, Wilkinson SB.

Neurology. 2000;55(12 Suppl 6):S29-33. Review.

PMID:
11188972

Supplemental Content

Loading ...
Support Center